Taiho Pharmaceutical Obtains Rights To Cancer Drug Yondelis From Spanish PharmaMar
This article was originally published in PharmAsia News
Tokyo-based Japanese drug maker Taiho Pharmaceutical March 31 signed a license agreement with Spain's PharmaMar SA on anticancer compound Yondelis (trabectedin). According to the agreement, Taiho obtained exclusive rights to develop and market in Japan. PharmMar receives an initial payment of ¥1 billion, as well as future payments and sales royalties in Japan. Taiho will also cover all development and marketing costs of Yondelis in Japan. Taiho is planning to start Phase I trials for Yondelis to treat soft tissue sarcoma and cervical cancer in Japan. (Click here for more - Japanese language
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.